FDA Recalls Xanax Due to Dissolution Failure

The U.S. Food and Drug Administration has issued a nationwide recall for a specific allotment of Xanax XR, an extended-release medication used to treat panic and anxiety disorders. The recall involves the brand-name product distributed by Viatris Specialty LLC, a company based in West Virginia.

The recall was triggered after the medication failed to meet dissolution specifications. According to FDA guidance, dissolution is the specific test used to determine how well a drug dissolves and releases when This proves placed in a liquid. A failure to meet these specifications can result in a medication that is less effective or provides an incorrect dosage to the patient.

Specific Product Details

The recall is limited to a single lot of the medication. The affected product is Xanax XR, identified as Lot #8177156, which consists of 3 mg extended-release tablets provided in 60-tablet bottles. These specific bottles have an expiration date of February 28, 2027.

According to the California State Board of Pharmacy, the impacted lot was distributed within the United States between August 27, 2024, and May 29, 2025.

Viatris Specialty has clarified that the recall is highly specific. A company spokesperson stated that the voluntary recall of Xanax XR is specific to one lot of one strength of the brand product only, and no other batches of the Xanax XR brand product, or its generics, are impacted. The spokesperson further noted that the vast majority of patients in the U.S. Are dispensed generic alprazolam, which is not affected by this action.

FDA Classification and Safety Status

The FDA has classified this recall as Class II. Under this classification, the use of or exposure to the violative product may cause temporary or medically reversible adverse health consequences, according to the agency.

Viatris first initiated the recall on March 17, and the FDA issued the formal recall notice on April 8. Despite the classification, FDA officials are not warning against the consumption of the product at this time. The California State Board of Pharmacy reported that the recall was conducted out of an abundance of caution and that there have been no reported adverse reactions related to this specific lot.

Medical Context and Usage

Xanax, the brand name for alprazolam, is a benzodiazepine indicated for the treatment of panic disorder in adults, with or without agoraphobia. It is also commonly prescribed for generalized anxiety disorder.

The medication works by enhancing the activity of specific neurotransmitters in the brain. While it is generally considered safe and helpful when used as directed, addiction experts note that it is a highly addictive substance due to psychodynamic properties that can create feelings of euphoria. When used as intended, the drug’s effects typically last up to six hours.

Because Xanax XR is an extended-release formulation, the dissolution rate is critical to ensuring the medication is released into the bloodstream at a steady, controlled pace over time. The failure of the dissolution test suggests that this controlled release mechanism may not be functioning as required for Lot #8177156.